G&S Capital’s Exact Sciences EXAS Stock Holding History

G&S Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,697	Closed	-$341K	–	203
2019 Q4	$341K	Buy	+3,697	New	+$325K	0.19%	72

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

G&S Capital's EXAS Position: Q1 2020 in Review

G&S Capital sold out of Exact Sciences (EXAS) in Q1 2020, closing a stake of 3,697 shares — an estimated $341K sold.

G&S Capital first reported a position in EXAS in Q4 2019 and held it in 1 quarter. The position peaked at $341K in Q4 2019. 476 funds tracked by Wall St. Rank hold EXAS as of Q1 2020.

G&S Capital reported no remaining Exact Sciences position as of Q1 2020 after selling out during the quarter.
G&S Capital sold 3,697 Exact Sciences shares in Q1 2020, an estimated $341K.
G&S Capital first reported a position in Exact Sciences in Q4 2019 and held it in 1 quarter.
G&S Capital's Exact Sciences position peaked at $341K in Q4 2019.
476 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2020.

Based on G&S Capital's 13F filing for Q1 2020, filed 23 Apr 2020.